Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 safety, pharmacokinetic and pharmacodynamic study of AG-024322, an inhibitor of cyclin-dependent kinase 1, 2 and 4, administered intravenously daily for 5 days every 3 weeks to patients with advanced cancer

Next Previous
X
Search
Trial Profile

A phase 1 safety, pharmacokinetic and pharmacodynamic study of AG-024322, an inhibitor of cyclin-dependent kinase 1, 2 and 4, administered intravenously daily for 5 days every 3 weeks to patients with advanced cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AG 24322 (Primary)
  • Indications Diffuse lymphoma; Follicular lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 15 Aug 2007 Status change from recruiting to discontinued.
    • 03 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top